Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03466320 · ClinicalTrials.gov registry record · Phase 1
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
A Phase 1 study of AML and MDS, sponsored by Celyad Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 7
- Study locations
NCT03466320 is a Phase 1 study of AML and MDS that has completed, run by Celyad Oncology. The registered enrollment target is 21 participants, below the 133-participant average among 29 other AML trials with a reported enrollment target (84% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT03466320, a Phase 1 study of AML and MDS, has completed, sponsored by Celyad Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 7
- Study locations
Study Summary
This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended investigational treatment option (schedule of preconditioning and NKR-2 dose) and the second segment will expand to a larger number of r/r AML/MDS patients.
Interventions
- BIOLOGICAL NKR-2
Study Locations (7)
Other
- Universitair Ziekenhuis Antwerpen - Antwerp
- Institute Jules Bordet - Brussels
- UZ Gent - Ghent
Colorado
- University of Colorado - Aurora
Florida
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., - Tampa
Georgia
- Emory University - Atlanta
New York
- New York School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-09-18 |
| Est. Completion | 2021-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03466320
The ClinicalTrials.gov registry entry for NCT03466320 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 133-participant average among 29 other AML trials with a reported enrollment target (84% lower). The listed sponsor is Celyad Oncology, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with AML appearing as the primary indexed condition, and to 1 intervention - of which NKR-2 is the first listed.
NCT03466320 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT03466320 about?
NCT03466320 is a clinical study titled "DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2". This open-label Phase I study aims at assessing primarily the safety of the NKR-2 treatment administered after a non-myeloablative preconditioning regimen in r/r AML/MDS patients. This Phase I study will contain two different sequential segments. The first segment will determine the recommended inv...
What is the current status of trial NCT03466320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-09-18. Estimated completion is 2021-02-01.
What conditions does trial NCT03466320 study?
This clinical trial studies the following conditions: AML, MDS.
What interventions are being tested in trial NCT03466320?
The interventions under investigation include: NKR-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03466320?
This trial is sponsored by Celyad Oncology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03466320 being conducted?
This trial has 7 study locations across Colorado, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AML
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
RECRUITING · Phase 1
-
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
CC-486 and Venetoclax for Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.